Sunday, March 29, 2026 – Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to reduced appetite and stronger feelings of fullness. In a study of more than 400 patients, roughly one in five experienced heightened taste sensitivity, and many reported being less hungry and more easily satisfied.

Sunday, March 29, 2026 – Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems tied not just to slimming down but to deeper biological effects on inflammation, blood pressure, and vessel health. Researchers say this could expand who qualifies for the drug.

Sunday, March 29, 2026 – Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels. With a safety profile consistent with existing treatments, experts see it as a breakthrough for patients preferring oral options.

Sunday, March 29, 2026 – Scientists are uncovering how GLP-1 drugs like Ozempic and Wegovy act on brain regions that control hunger, nausea, pleasure-based eating, and thirst. These discoveries may help create treatments that keep the benefits of weight loss while reducing unwanted side effects.

Sunday, March 29, 2026 – Audience: Consumer PLAINSBORO, NJ, December 5, 2025 – FDA recently seized dozens of units of counterfeit Ozempic (semaglutide) injection 1 mg distributed illegally outside of Novo Nordisk’s authorized supply chain. The US Food and Drug…

Sunday, March 29, 2026 – Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quieted the nucleus accumbens, the brain’s reward hub.

Sunday, March 29, 2026 – Bariatric surgery far outperformed GLP-1 weight loss drugs in a new real-world comparison of more than 50,000 patients. Two years after treatment, surgery patients lost about 58 pounds on average, while those using semaglutide or tirzepatide lost roughly 12 pounds. Even patients who stayed on GLP-1 drugs for a full year saw much smaller results than surgical patients. High dropout rates and real-world challenges appear to blunt the drugs’ effectiveness.

Sunday, March 29, 2026 – Audience: Health Care Professional, Consumer January 13, 2026

FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety…

Sunday, March 29, 2026 – Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.

Sunday, March 29, 2026 – Could weight-loss drugs shrink the body representation we’ve spent decades seeking?

Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, February 24, 2026 –Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide)…

Sunday, March 29, 2026 – INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral GLP-1…

Sunday, March 29, 2026 – South San Francisco, CA — March 5, 2026 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493…

Sunday, March 29, 2026 – Plainsboro, NJ, US and Bagsværd, Denmark, 09 March 2026 – Novo Nordisk today announced it has reached an agreement with telehealth company Hims & Hers that will take effect later this month. Under the terms of the agreement, Hims…

Sunday, March 29, 2026 – NORTH CHICAGO, Ill., March 9, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and…

Sunday, March 29, 2026 – (MedPage Today) — The obesity drug semaglutide (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of FDA data showed.
In a…

Sunday, March 29, 2026 – A Stanford study shows simple digital prompts can motivate people taking GLP-1 medications to make lifestyle changes. It’s a simple premise: What if something as small as a digital nudge could put someone on the path to healthier habits while taking GLP-1 medications?

Sunday, March 29, 2026 – (MedPage Today) — GLP-1 receptor agonist use was associated with a lower risk of death in cancer patients with brain metastases and type 2 diabetes, a retrospective cohort study found.
Within 3 years of a first recorded brain metastasis, patients…

Sunday, March 29, 2026 – (MedPage Today) — The FDA issued a warning letter to Novo Nordisk for failing to report and investigate potentially serious side effects associated with its popular GLP-1 medications.
In a letter dated March 5 and made public on Tuesday, the…

Sunday, March 29, 2026 – (MedPage Today) — Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday.
Following laboratory testing, the drugmaker said it uncovered…

Sunday, March 29, 2026 – Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I study will evaluate UX-GIP001 in patients with drug-resistant epilepsy.

Sunday, March 29, 2026 – (MedPage Today) — Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn’t held prior to upper endoscopy unless they were on a clear liquid diet the day before, the OCULUS randomized trial…

Sunday, March 29, 2026 – (MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation…

Sunday, March 29, 2026 – The GLP-1 fight has moved from injectables to pills, and Structure Therapeutics Inc. is in the ring with phase III-ready aleniglipron. According to the Bay Area biotech, its oral once-daily glucagon-like peptide-1 (GLP-1) drug candidate, aleniglipron, demonstrated an absolute weight loss of “up to 39 pounds” in the 44-week Access II trial.

Sunday, March 29, 2026 – Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to treat pre-existing diabetes. However, a large study of over 750,000 pregnancies found that there was no link to preterm births or other obstetric complications if the medication was being used to lose weight. The authors of the study, published in Human Reproduction Open, say their findings suggest that it is diabetes rather than the drugs that may be contributing to the increased risk of preterm births.

Sunday, March 29, 2026 – Following a rapid increase in popularity of GLP-1 drugs for diabetes and weight loss, such as semaglutide and tirzepatide, approximately one in eight U.S. adults now take these medications, which also provide cardiovascular benefits. However, when patients stop taking these drugs, they not only regain weight, but, according to a new study, they also incur increased risk of heart attack, stroke, and death compared to staying on the medication.

Sunday, March 29, 2026 – The study findings may spark treatment innovations for depression and anxiety.

Sunday, March 29, 2026 – GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows. The large register-based study was carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia.

Sunday, March 29, 2026 – In a sea of uncertainty, a large-scale, long-term Swedish study is the first to show that people using GLP-1 receptor agonists are less likely to have worsening mental illness. The study involved a national cohort of 95,490 people diagnosed with depression or anxiety disorder, who also were treated with any diabetes drug (apart from insulin).

Sunday, March 29, 2026 – INDIANAPOLIS, March 19, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational…

Sunday, March 29, 2026 – (MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose — three times the strength…

Sunday, March 29, 2026 – A stronger version of the popular weight loss drug Wegovy is on the way after federal regulators signed off on a higher dose. The U.S. Food and Drug Administration (FDA) approved a 7.2-milligram dose of Novo Nordisk’s semaglutide, the active ingredient in Wegovy. Until now, the highest approved dose was 2.4 milligrams, taken as a weekly shot.

Sunday, March 29, 2026 – Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.

Sunday, March 29, 2026 – This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.

Sunday, March 29, 2026 – WEDNESDAY, March 25, 2026 — Glucagon-like peptide-1 (GLP-1) receptor agonists, especially semaglutide, are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and obesity, according to a study…

Sunday, March 29, 2026 – In new research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May), a global panel of 21 obesity and cancer experts suggest that to test the potential efficacy of the new generation of obesity drugs such as semaglutide and tirzepatide in preventing obesity-related cancer (ORC), a trial of the drugs for some 5,000 participants at high risk of cancer due to their having a cancer pre-cursor condition will provide the required answers.

Sunday, March 29, 2026 – A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available counterparts, according to a recent trial. The drug, known as orforglipron, could be a game-changer in the rapidly expanding oral weight-loss drug market.

Sunday, March 29, 2026 – So you’ve decided to go on a GLP-1 to lose weight. These medicines might seem like an easy way to drop unwanted pounds, but you’ll likely need to do a few other things to be successful long-term.

Sunday, March 29, 2026 – (MedPage Today) — People with pre-existing depression or anxiety were less likely to have mental health worsening while taking a GLP-1 medication, observational Swedish data suggested.
Compared with periods of non-use in the same individual…

Sunday, March 29, 2026 – These medications could be one reason why weight room floors seem busier than ever.